El interés en corto de Biohaven da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Biohaven. Los datos de interés en corto se actualizan cada dos semanas.

Biohaven (NYSE:BHVN) Bolsa, Informe de interés en corto

Biohaven

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Biohaven Pharma Hldgs

Biohaven Pharmaceutical

Biohaven Ltd

WIIM

ARCO

Arcos Dorados shares are trading higher after the company announced plans to exercise its option to new its master franchise agreement with McDonald's.

CoStar Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NYSE">CSGP</a>) short percent of float has risen 8.72% since its last report. The company recently reported that it has 8.09 million shares sold short, which is 2.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.35 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>CoStar Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727789427_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CoStar Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing CoStar Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, CoStar Gr's peer group average for short interest as a percentage of float is 6.41%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

CSGP

How Is The Market Feeling About CoStar Gr?

Novavax's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NYSE">NVAX</a>) short percent of float has risen 6.09% since its last report. The company recently reported that it has 33.53 million shares sold short, which is 26.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novavax Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727789422_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novavax has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Novavax's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novavax's peer group average for short interest as a percentage of float is 13.61%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

NVAX

Looking Into Novavax's Recent Short Interest

Zoom Video Comms's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NYSE">ZM</a>) short percent of float has fallen 12.19% since its last report. The company recently reported that it has 9.23 million shares sold short, which is 3.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Zoom Video Comms Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727789417_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zoom Video Comms has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Zoom Video Comms's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Zoom Video Comms's peer group average for short interest as a percentage of float is 3.17%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Zoom Video Comms's Recent Short Interest

Citigroup analyst Patrick Donnelly downgrades Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Neutral to Sell and lowers the price target from $215 to $175.

News

Downgrades

Price Target

Analyst Ratings

Citigroup Downgrades Charles River to Sell, Lowers Price Target to $175

Zeekr shares are trading higher after the company delivered 21,333 vehicles in September 2024, a 77% year-over-year increase.

GRTS

Gritstone Bio shares are trading lower after JMP Securities downgraded the stock from Market Outperform to Market Perform.

Despegar.com, Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) ("Despegar" or the "Company"), Latin America's leading travel technology company and Nubank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>), the largest digital banking platform outside Asia, today announced the integration of NuPay as a new payment option on Despegar's travel platform.
The collaboration between Nubank and Despegar offers multiple strategic benefits for both companies, including:
<ol>
<li>Despegar gains access to Nubank's 95.5 million Brazilian customers, broadening its target market significantly</li>
<li>Nubank's customers will gain access to Despegar's travel platform and services enjoying increased spending limits and enhanced purchasing power through a variety of payment options, including debit and credit</li>
<li>The partnership creates a more streamlined payment process, boosting Despegar's conversion rates while offering greater convenience to both companies' users</li>
</ol>
Combining Nubank's extensive customer base with Despegar's seamless travel services allows both companies to capitalize on their strengths delivering enhanced value to their customers and paves the way for new opportunities and an improved user experience.

DESP

Nubank And Despegar Announce Integration Of Nupay As A New Payment Option On Despegar's Travel Platform

SGMT

Sagimet Biosciences shares are trading higher after the company announced it was granted an FDA Breakthrough Therapy Designation for Denifanstat for noncirrhotic metabolic dysfunction associated steatohepatitis with moderate to advanced liver fibrosis.

Lexaria Bioscience Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>) &amp; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXXW#NASDAQ">LEXXW</a>) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Michael Shankman, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of the executive leadership team, Mr. Shankman will lead the Company's financial operations.

Management

LEXX

LEXXW

Lexaria Appoints Michael Shankman As Chief Financial Officer, Effective Immediately

B of A Securities analyst Lawson Winder upgrades Steel Dynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) from Neutral to Buy and raises the price target from $140 to $155.

Upgrades

STLD

B of A Securities Upgrades Steel Dynamics to Buy, Raises Price Target to $155

PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) ("PepsiCo") today announced that it has entered into a definitive agreement to acquire Garza Food Ventures LLC, dba Siete Foods ("Siete") for $1.2 billion.&nbsp;
The acquisition will complement PepsiCo's portfolio with the addition of an authentic, Mexican-American brand, while also growing its better-for-you food offerings. Siete products will bring a rich, new aspect to the PepsiCo multicultural portfolio with delicious food that plays an important role in meal occasions and culinary experiences.&nbsp;
Founded in 2014, Siete produces authentic heritage-inspired tortillas, salsas, seasonings, sauces, cookies, snacks and more. Siete's products can be found in grocery stores, club stores, and organic food retailers primarily across the U.S.&nbsp;

PepsiCo Has Entered Into A Definitive Agreement To Acquire Garza Food Ventures, dba 'Siete Foods' For $1.2B

Governor Gavin Newsom's <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">emergency hemp restrictions </a>have officially gone into effect, sparking concerns and discussions within the cannabis industry. These new regulations, aimed at severely limiting hemp-derived products, are already causing ripples in the marketplace. The impact on the cannabis and hemp sectors, as well as implications for investors and patients, remains a critical focus, especially given California's significant influence on national cannabis policy.
Will Bowden, CEO of Grasshopper Farms and a speaker at the upcoming <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference </a>offered his perspective on the new regulations. 
Bowden believes that while the restrictions may initially disrupt the market, they are ultimately necessary to ensure safety and protect consumers.
See Also: <a href="https://www.benzinga.com/personal-finance/24/09/41082125/stop-ripping-us-off-incredibly-elon-musk-and-bernie-sanders-seem-to-agree-on-this-one-thing-i-re" target="_blank" rel="noreferrer noopener">‘Stop Ripping Us Off,' Elon Musk And Bernie Sanders Seem To Agree On This One Thing</a>
<h3 class="wp-block-heading">Safety First in Cannabis and Hemp Products</h3>
Bowden has been vocal about the safety concerns surrounding unregulated hemp-derived products, particularly those that are sold with little oversight. "There is a lot of ‘hemp' derived products that are being passed off as similar or the same as those offered through a state commercial cannabis program, but with no controls on who purchases and requirements for the products," Bowden explained. He sees the new restrictions as a crucial step toward addressing these concerns.
By tightening the regulations around hemp products, Bowden hopes that other states will take note and adopt similar measures. "I do hope that other states are able to do the same," he said, reinforcing the need for consistent safety standards across the industry.
<h3 class="wp-block-heading">Broader Impact on the Market</h3>
California's new hemp restrictions are likely to have far-reaching effects in the state and across the country. Bowden highlighted the risk of unregulated hemp products flooding other states, a concern that has already begun to materialize. "With California being so large, there is a risk of this activity flooding the rest of the U.S., which is already happening to some extent," Bowden noted.
The new regulations may force other states to consider similar restrictions to prevent the influx of unregulated hemp products into their markets. For the cannabis industry, these changes could provide a more clearly defined separation between hemp and state-regulated cannabis products, potentially leading to a safer and more transparent marketplace.
<h3 class="wp-block-heading">Investor and Patient Implications</h3>
These new regulations will likely have consequences for industry investors and patients. Investors who were previously involved in hemp-derived products may now need to pivot toward more regulated opportunities within the cannabis space. Additionally, patients who rely on hemp-based products for medical purposes may face challenges in accessing these products as availability declines under the new rules.
The upcoming <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a> will offer a platform for industry leaders like Bowden to explore these issues further and discuss the evolving landscape of cannabis regulation.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/41093983/no-companies-will-invest-how-californias-hemp-rules-could-hurt-cannabis-businesses">&#8216;No Companies Will Invest&#8217;: How California&#8217;s Hemp Rules Could Hurt Cannabis Businesses</a></li>
</ul>
Image: Pixabay

Cannabis

Politics

Events

Exclusives

Interview

How Will California's Hemp Restrictions Change The Cannabis Market: 'There Is A Risk Of This Activity Flooding The US' Says Expert

Citigroup analyst Patrick Donnelly upgrades Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) from Neutral to Buy and raises the price target from $350 to $400.

Citigroup Upgrades Bio-Rad Laboratories to Buy, Raises Price Target to $400

GHSI

Guardion Health Sciences shares are trading lower after the company announced it adopted a plan of dissolution and liquidation. Also, it will delist form the Nasdaq and appoint an interim president and CEO.

Citigroup analyst Asiya Merchant downgrades HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) from Buy to Neutral and maintains the price target from $37 to $37.

Citigroup Downgrades HP to Neutral, Maintains Price Target to $37

MGRX

Mangoceuticals shares are trading higher after the company announced its oral semaglutide branded as "Slim" is now available on their website.

Ford Motor shares are trading higher after Goldman Sachs upgraded the stock from Neutral to Buy and raised its price target to $13.

Charles Schwab Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) CEO Walt Bettinger will retire at the end of 2024. Rick Wurster, the current president, will succeed him starting Jan. 1, 2025.
What Happened: Bettinger, who turns 65 next year, cited his upcoming birthday as a reason for stepping down. He will continue to serve as co-chair of Schwab&#8217;s board. In a statement, Bettinger expressed confidence in Wurster&#8217;s leadership, noting their eight-year working relationship, CNBC <a href="https://www.cnbc.com/2024/10/01/charles-schwab-ceo-walt-bettinger-to-retire-at-end-of-2024-rick-wurster-to-replace-him.html">reported</a> on Tuesday.
Wurster, in an interview on CNBC&#8217;s &#8220;Squawk Box,&#8221; assured that there would be no immediate strategic changes. &#8220;We&#8217;re going to continue what we&#8217;ve been doing, which is deliver for our clients and delight them,&#8221; he said.
Under Bettinger&#8217;s leadership since 2008, Schwab&#8217;s client assets surged from $1.14 trillion to $9.74 trillion, partly due to the acquisition of TD Ameritrade in 2020. Bettinger mentioned the completion of Ameritrade&#8217;s integration as another reason for his decision to retire.
Schwab&#8217;s stock has risen approximately 150% during Bettinger&#8217;s tenure, despite underperforming the broader market in the past two years. Shares of Schwab were up less than 1% in premarket trading on Tuesday.
See Also: <a href="https://www.benzinga.com/news/24/09/41082667/heres-why-china-is-urging-its-companies-to-forgo-nvidias-chips?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Here&#8217;s Why China is Urging Its Companies to Forgo Nvidia&#8217;s Chips</a>
Why It Matters: Bettinger&#8217;s retirement comes at a pivotal time for Charles Schwab. In August, Toronto-Dominion Bank <a href="https://www.benzinga.com/markets/equities/24/08/40500034/charles-schwab-shares-drop-over-4-after-hours-as-td-bank-cuts-stake-following-2-6b-anti-money-la">reduced its stake</a> in Schwab, selling 40.5 million shares. This move followed TD Bank&#8217;s announcement of setting aside $2.6 billion to cover potential fines related to deficiencies in its anti-money laundering program.
The sale reduced TD Bank&#8217;s ownership in Schwab from 12.3% to 10.1%, impacting Schwab&#8217;s stock price. TD Bank&#8217;s decision was influenced by ongoing investigations into its anti-money laundering practices, which have been under scrutiny due to allegations involving Chinese drug traffickers laundering money through the bank.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41084992/nvidia-stock-could-touch-800-by-2030-bgg-executive-predicts-550-upside-driven-by-ai-revolution-a?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Nvidia Stock Could Touch $800 By 2030, BGG Executive Predicts 550% Upside Driven By AI Revolution And Web3 Transition</a></li>
</ul>
Image via Flickr
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Markets

General

SCHW

Charles Schwab's CEO Bettinger Announces Retirement, Names President Rick Wurster As Successor

Goldman Sachs analyst Mark Delaney maintains Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) with a Buy and lowers the price target from $24 to $20.

MBLY

Goldman Sachs Maintains Buy on Mobileye Global, Lowers Price Target to $20

RBC Capital analyst Leonid Timashev maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) yesterday and set a price target of $68.00. T...

RBC Capital Remains a Buy on Biohaven Ltd. (BHVN)

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) and keeping the price target at $58.00....

Buy Rating Affirmed for Biohaven Ltd. on Strong Potential of Troriluzole for Spinocerebellar Ataxia

Analyst Thomas Shrader from BTIG maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) and keeping the price target at $59.00. Thomas S...

Buy Rating for Biohaven's Troriluzole Backed by Long-Term Efficacy Data and Positive Regulatory Outlook

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Biohaven Ltd. (BHVN – Research Report) yesterday and set a price targe...

Buy Rating Affirmed for Biohaven Ltd. on Promising Troriluzole SCA Program Data and Potential Market Dominance

In a report released yesterday, William Pickering from Bernstein maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report), with a price ta...

Bernstein Remains a Buy on Biohaven Ltd. (BHVN)

J.P. Morgan analyst Tessa Romero has maintained their bullish stance on BHVN stock, giving a Buy rating today. Tessa Romero has given his Buy ratin...

Buy Rating Affirmed for Biohaven on Promising Troriluzole SCA Study Results and FDA Approval Potential

Biohaven Ltd. (BHVN) has received a new Buy rating, initiated by Jefferies analyst, Amy Li. Amy Li's rating is based on the promising outcomes of B...

Biohaven Ltd.: Strong Buy Rating on Troriluzole's Promising SCA Study and FDA Alignment

Biohaven proposed public offering of common shares

Biohaven prices $250M share offering

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report), with a price target of...

TD Cowen Sticks to Its Buy Rating for Biohaven Ltd. (BHVN)

BHVN

Earnings

Press Releases

Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors

Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day

Health Care

Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments

Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

Offerings

Biohaven Announces Proposed Public Offering of Common Shares

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares

BNTC

REGN

Arcellx

ADMA Biologics

Alkermes

Alvotech

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

BridgeBio Pharma

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Denali Therapeutics

Dyne Therapeutics

Exelixis

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Immunovant

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Nuvalent

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Comments

Biohaven

Interés en corto

Biohaven (NYSE:BHVN) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL